Pancreatic Cancer Research

ResearcherGuangdong Academy of Medical SciencesActive in the last 2 years

Yao Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-1479-9672; OpenAlex author ID A5057325915. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 5

  1. Correction: circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-026-02730-6↗
  2. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3997↗
  3. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. Co-author DOI 10.1172/jci157644↗
  4. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. Co-author DOI 10.1186/s12943-020-01196-4↗
  5. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01205-6↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changhao Chen · 5 shared papers, 2020–2026 · strength 0.80
  2. Yuming Luo · 5 shared papers, 2020–2026 · strength 0.80
  3. Rufu Chen · 3 shared papers, 2022–2026 · strength 0.59
  4. Xiaofeng Guo · 3 shared papers, 2020–2026 · strength 0.50
  5. Zhihua Li · 3 shared papers, 2020–2026 · strength 0.50
  6. Jiabin Yang · 2 shared papers, 2022–2023 · strength 0.30
  7. Dingwen Zhang · 2 shared papers, 2022–2023 · strength 0.30
  8. Y P. Li · 1 shared paper, 2026 · strength 0.29
  9. Rufu Chen · 2 shared papers, 2020 · strength 0.21
  10. Shangyou Zheng · 1 shared paper, 2023 · strength 0.16
  11. Zhihua Li · 1 shared paper, 2022 · strength 0.14
  12. Zhiqiang Fu · 1 shared paper, 2020 · strength 0.10
  13. Leyi Huang · 1 shared paper, 2020 · strength 0.10
  14. Quanbo Zhou · 1 shared paper, 2020 · strength 0.10
  15. Zhiguo Li · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.